A Single Center, Double-Blind, Placebo-Controlled Phase I Single-Dose Cross-Over Study in Healthy Subjects to Investigate the Inhibitory Effect of CG100649, Celecoxib, Naproxen, and Acetazolamide on the Activity of Cyclooxygenases (COX-1, COX-2) and Carbonic Anhydrases (CA-I, CA-II)

Trial Profile

A Single Center, Double-Blind, Placebo-Controlled Phase I Single-Dose Cross-Over Study in Healthy Subjects to Investigate the Inhibitory Effect of CG100649, Celecoxib, Naproxen, and Acetazolamide on the Activity of Cyclooxygenases (COX-1, COX-2) and Carbonic Anhydrases (CA-I, CA-II)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Polmacoxib (Primary) ; Acetazolamide; Celecoxib; Naproxen
  • Indications Acute pain; Ankylosing spondylitis; Back pain; Bladder cancer; Dysmenorrhoea; Gouty arthritis; Juvenile rheumatoid arthritis; Non-small cell lung cancer; Osteoarthritis; Pain; Postoperative pain; Prostate cancer; Rheumatic disorders; Rheumatoid arthritis; Seizures
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Feb 2014 Status changed from active, no longer recruiting to discontinued as reported by the ClinicalTrials.gov record.
    • 16 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 25 Jan 2012 Results published in the Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top